FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| | | 3 , | | | |
|------------------|------------------|----------|-----------|----------------|----|
| | | | | | |
| STATEMENT | OF CHANGE | ES IN BE | ENEFICIAL | OWNERSH | ΙP |

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-028 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(First)

C/O EDESA BIOTECH INC.

(Last)

(Middle)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Nijhawan Pardeep | | 2. Issuer Name and Ticker or Trading Symbol Edesa Biotech, Inc. [EDSA] | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title Other (specify) | | | | | | | | |
|--|---|--|---|---|-------|--|--|--|---|--|--|------------------------------|--|-------------|---|--|-----------|
| | (Fi ESA BIOT COURT | , | Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 03/24/2021 | | | | | | X Ollicer (give title Other (specify below) Chief Executive Officer | | | | | | | |
| | | | | 4. If A | mendm | ent, Da | ate of O | riginal | Filed (Month/ | /Day/Yea | | . Individual o | r Joint | /Group Fili | ng (C | heck Ap | plicable |
| (Street) MARKHAM A6 L3R 5H6 | | | | | | | | | | Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person | | | | | | | |
| (City) | (S | tate) (2 | Zip) | | | | | | | | | 1 0100 | J11 | | | | |
| | | Table | I - Non-Deriva | ative S | ecuri | ties A | Acqui | red, I | Disposed | of, or | Benefic | ially Own | ed | | | | |
| Date | | 2. Transaction Date (Month/Day/Ye | ear) Ex | . Deeme ecution l iny onth/Day | Date, | | action (Instr. | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an 5) | | d (A) or r. 3, 4 and | 5. Amount of Securities Beneficially Owned Followin Reported | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | Code | v | Amount | (A) or (D) | Price | Transaction (Instr. 3 and | (s) 4) | , , | | | |
| Common | Shares | | 03/24/202 | 1 | | | P | | 5,000 | A | \$5.16 | 542,31 | 2 | D | | | |
| Common | Shares | | | | | | | | | | | 2,128,6 | 52 | I | | | ep wan |
| Common | Shares | | | | | | | | | | | 224,09 | 4 | I | | Diges | h Clinic |
| Common | Shares | | | | | | | | | | | 371,72 | 7 | I | | Held 19681 Ontar | |
| | | Tal | ble II - Derivati (e.g., pt | | | | | | sposed o | | | | d | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) 5. Nun of Deriva Securi Acquii (A) or Dispos of (D) | | 5. Num of Derivat Securit Acquire (A) or Dispos of (D) (Instr. 3 | ber 6. Date Exercisable and Expiration Date (Month/Day/Year) ed ed | | d 7. Ti Amo Sec Und Deri | tle and ount of urities erlying vative urity (Instr. | 8. Price of Derivative Security (Instr. 5) (Instr. 5) 8. Price of deriv Security Security Follo Repo | | urities Forr eficially Dire or lr owing (I) (I orted isaction(s) | | ership n: ct (D) direct nstr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) (| | ate kercisal | Expiration Date | on Title | Amount or Number of Shares | | | | | | |
| | nd Address o r <mark>an Parde</mark> | f Reporting Person [*] <u>ep</u> | | | | | | | | | | | | | | | |
| | ESA BIOT | (First) ECH INC. | (Middle) | | | | | | | | | | | | | | |
| (Street) MARKE | IAM | A6 | L3R 5H6 | | - | | | | | | | | | | | | |
| (City) | | (State) | (Zip) | | | | | | | | | | | | | | |
| | | f Reporting Person* an Medicine l | Professional (| <u>Corp</u> | - | | | | | | | | | | | | |

| 100 SPY COUR | Γ | |
|------------------|---------|---------|
| (Street) MARKHAM | A6 | L3R 5H6 |
| (City) | (State) | (Zip) |

Explanation of Responses:

 $1.\ Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Pardeep Nijhawan Professional Corporation and Professio$

/s/ Pardeep Nijhawan 03/25/2021

/s/ Pardeep Nijhawan

Medicine Professional

Corporation by Pardens

03/25/2021

Corporation, by Pardeep

<u>Nijhawan</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.